MDYG - ETF AI Analysis
Top Page
SPDR S&P 400 Mid Cap Growth ETF (MDYG)
MDYG vs. SPDR S&P 500 ETF (SPY)
- AUM
- 2.83B
- Region
- North America
- Expense Ratio
- 0.15%
- Beta
- 1.01
- Issuer
- SPDR
- Inception Date
- Nov 08, 2005
- Dividend Yield
- 0.70%
- Asset Class
- Equity
- Index Tracked
- S&P Mid Cap 400 Growth
MDYG Summary
MDYG is the SPDR S&P 400 Mid Cap Growth ETF, which follows the S&P MidCap 400 Growth Index. It invests in medium‑sized U.S. companies that are growing quickly, across sectors like industrials, technology, and health care. Well-known holdings include Okta and Roku. Someone might invest in MDYG to tap into the growth potential of mid-sized companies while spreading their money across many different stocks for diversification. A key risk is that growth-focused mid-cap stocks can be more volatile, so the ETF’s value can go up and down sharply with the market.
How much will it cost me?
This ETF has an expense ratio of 0.15%, which means you’ll pay about $1.50 per year for every $1,000 you invest. That’s lower than the average stock ETF because it’s passively managed and simply tracks the S&P MidCap 400 Growth Index instead of paying managers to pick individual stocks.
What would affect this ETF?
MDYG could benefit if the U.S. economy continues to grow, supporting mid-sized industrial, technology, and health care companies like Okta, United Therapeutics, and Roku, and if investor appetite for growth stocks remains strong as interest rates stabilize or decline. On the downside, higher interest rates, an economic slowdown in the U.S., or regulatory and competitive pressures on tech and health care firms could hurt the fund’s growth-focused mid-cap holdings and make this ETF more volatile.
MDYG Top 10 Holdings
MDYG leans heavily into U.S. mid-cap growth, with a clear tilt toward tech, industrials, and health care names. Okta and Dynatrace are two of the fund’s rising software stars, helping drive recent gains as demand for digital security and analytics stays strong. United Therapeutics and Tenet Healthcare add steady health care strength to the mix. On the flip side, industrial players like ATI and nVent Electric have seen more mixed, recently lagging action, occasionally acting as a speed bump for performance rather than a turbo boost.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 OKTA | Okta | ― | ― | ― | ― | 75Outperform |
 FTI | TechnipFMC | 1.47% | $41.57M | $25.08B | 45.47% | 80Outperform |
 UTHR | United Therapeutics | 1.52% | $42.91M | $26.10B | 26.43% | 79Outperform |
 ATI | ATI | 1.42% | $40.08M | $24.32B | 74.46% | 78Outperform |
 XPO | XPO | 1.28% | $36.19M | $21.91B | 27.57% | 70Outperform |
 THC | Tenet Healthcare | 1.37% | $38.67M | $23.26B | 37.31% | 74Outperform |
 ROKU | Roku | 1.25% | $35.32M | $24.27B | 51.76% | 65Neutral |
 NVT | nVent Electric | 1.06% | $30.01M | $18.23B | -12.55% | 76Outperform |
 RGLD | Royal Gold | 1.21% | $34.26M | $20.85B | 50.75% | 78Outperform |
 WWD | Woodward | 1.12% | $31.67M | $19.27B | 16.98% | 79Outperform |
MDYG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MDYG, the sentiment is Negative. The current price of 99.70 is below the 20-day moving average (MA) of 103.88, below the 50-day MA of 105.26, and below the 200-day MA of 104.38, indicating a bearish trend. The MACD of -0.82 indicates Positive momentum. The RSI at 34.95 is Neutral, neither overbought nor oversold. The STOCH value of 51.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDYG.
MDYG Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| MDYG | $99.70 | $116.00(16.35% Upside) | $2.83B | 0.15% | 72Outperform |
 IJK | $104.55 | $136.43(30.49% Upside) | $10.51B | 0.16% | 72Outperform |
 IJJ | $143.39 | $171.44(19.56% Upside) | $8.90B | 0.18% | 70Neutral |
 FMDE | $40.66 | $49.22(21.06% Upside) | $8.85B | 0.23% | 69Neutral |
 IMCG | $89.73 | $115.29(28.48% Upside) | $4.07B | 0.06% | 69Neutral |
 IVOG | $130.25 | $182.23(39.91% Upside) | $1.69B | 0.10% | 71Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MDYG | SPDR S&P 400 Mid Cap Growth ETF | 99.70 | 8.02 | 8.75% | |
| IJK | iShares S&P Mid-Cap 400 Growth ETF | 104.55 | 8.42 | 8.76% | |
| IJJ | iShares S&P Mid-Cap 400 Value ETF | 143.39 | 16.82 | 13.29% | |
| FMDE | Fidelity Enhanced Mid Cap ETF | 40.66 | 5.11 | 14.39% | |
| IMCG | iShares Morningstar Mid-Cap Growth ETF | 89.73 | 8.33 | 10.23% | |
| IVOG | Vanguard S&P Mid-Cap 400 Growth ETF | 130.25 | 10.52 | 8.79% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.